You just read:

NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

News provided by

NeuroDerm Ltd

Apr 15, 2013, 09:25 ET